Tagged with OP

Opinion Pharmaceutical innovation is racing ahead of the US health system’s ability to adjust payment models, but innovative concepts are finally emerging. We will have to move beyond siloed thinking to establish them for the sake of getting patients sustainable access to a new wave of transformative cures, argues Ulrich Neumann.…

UK Jameel Zayed of Leyton, the UK’s leading innovation funding consultancy, highlights the British pharmaceutical industry’s rapid response to COVID-19 and the three ways in which the sector is driving national innovation forwards.   With the upheaval of recent months, businesses up and down the UK have been forced to adapt…

GSK GSK, the world’s largest manufacturer of vaccines, has pursued a different strategy to that of its contemporaries in the effort to develop a safe, effective, and mass-producible COVID-19 vaccine. PharmaBoardroom recently spoke to Emmanuel Hanon, GSK’s senior VP for vaccines R&D, to get his take on the company’s unique role…

USA French firm LFB is targeting the lucrative US market with its hemophilia products and recently received two FDA approvals. Although launching new products in the midst of a global pandemic is not without challenges, LFB USA CEO Jose Antonio Moreno Toscano is optimistic that the launches will be a success…

Belgium Alexander Alonso, general manager of medtech giant BD’s operations in Belgium, the Netherlands, and Luxembourg outlines the company’s extensive footprint in the region, how it has rapidly mobilised in the fight against COVID-19, and the market access situation for innovative medtech solutions in Belgium today.   In Benelux there is…

Belgium Philippe de Pougnadoresse, country president & general manager pharma for Novartis Belgium & Luxembourg, outlines his affiliate’s fast and comprehensive response to the COVID-19 crisis, what can be learned from it, the importance of Belgium to the European group, and the challenges of launching gene therapy Zolgensma® in Belgium.  …

France French pharma giant Sanofi is pivoting its focus to invest more heavily in vaccines with a plan to invest USD 679 million in vaccine manufacturing operations in the next two years. This announcement came shortly after news of further rounds of layoffs of research staff working on cardiovascular diseases and…

USA Dan Leonard, Kimberly Westrich, and Brian Sils of the National Pharmaceutical Council examine how a new HHS ruling on how US patients pay for medicines could hurt them financially, exacerbating what is already a challenging time in the midst of the COVID-19 pandemic.   The pandemic has been a challenging…

Pharma Faces Veronique Walsh, general manager of Bristol Myers Squibb for Belgium, the Netherlands, and Luxembourg (Benelux), recently spoke to PharmaBoardroom about her diverse career path, transitioning from medical doctor to pharmaceutical executive, and leading a large affiliate through the COVID-19 crisis.   Looking back over her slightly unusual career trajectory, Walsh,…

Merck Merck KGaA has moved to continuously expand its manufacturing capacity and capability in recent years with a number of headline-grabbing investments in sites in its home market of Germany and across the world. Moreover, the company is now increasingly at the forefront of digitalisation and innovation in its manufacturing and…

Europe The European Medicines Agency (EMA), Europe’s regulatory body for medicines, has nominated Irish candidate Emer Cooke to as its new executive director at a crucial time for the agency as its powers and priorities shift in the wake of the COVID-19 crisis.   If Cooke accepts and gives an official…

Italy Below we present recent news from Italy’s biopharma industry, including the recent acquisition of Stemline Therapeutics by Menarini, research collaboration between Italy and China, labelling regulations, a new biotech sector report and new studies on antibodies against Covid-19.   Menarini gains presence in US oncology market with acquisition of Stemline…